Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Castle Biosciences Inc Market Cap
From what 9 stock analysts predict, the share price for Castle Biosciences Inc (CSTL) might increase by 40.25% in the next year. This is based on a 12-month average estimation for CSTL. Price targets go from $36 to $50. The majority of stock analysts believe CSTL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 9 Wall Street analysts have assignedCSTL 9 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Castle Biosciences Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CSTL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CSTL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sung Ji Nam Scotiabank | Sector Outperform | $44 | Maintains | Nov 6, 2024 |
| Paul Knight Keybanc | Overweight | $36 | Maintains | Nov 5, 2024 |
| Thomas Flaten Lake Street | Buy | $40 | Maintains | Nov 5, 2024 |
| Catherine Ramsey Baird | Outperform | $39 | Maintains | Nov 5, 2024 |
| Kyle Mikson Canaccord Genuity | Buy | $42 | Maintains | Oct 29, 2024 |
| Sung Ji Nam BTIG | Buy | $40 | Maintains | Oct 14, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $37 | Reiterates | Aug 6, 2024 |
| Catherine Ramsey Baird | Outperform | $37 | Maintains | Aug 6, 2024 |
| Catherine Ramsey Baird | Outperform | $34 | Maintains | Jul 5, 2024 |
| Catherine Ramsey Baird | Outperform | $34 | Maintains | May 3, 2024 |
| Sung Ji Nam Scotiabank | Sector Outperform | $37 | Maintains | Mar 1, 2024 |
| Paul Knight Keybanc | Overweight | $28 | Maintains | Mar 1, 2024 |
| Subbu Nambi Guggenheim | Buy | $25 | Initiates | Dec 14, 2023 |
| Paul Knight Keybanc | Overweight | $25 | Maintains | Aug 4, 2023 |
| Thomas Flaten Lake Street | Buy | $32 | Reiterates | Jul 7, 2023 |
Stephens & Co. | Overweight | Reiterates | Jul 7, 2023 | |
| Mason Carrico Stephens & Co. | Overweight | $37 | Reiterates | Jul 6, 2023 |
| Mark Massaro BTIG | Buy | $30 | Maintains | Jun 15, 2023 |
Scotiabank | Sector Outperform | Maintains | Jun 7, 2023 | |
Canaccord Genuity | Buy | Maintains | Jun 6, 2023 |
When did it IPO
N/A
Staff Count
710
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Derek J. Maetzold
Market Cap
$873.5M
In 2023, CSTL generated $219.8M in revenue, which was a increase of 60.38% from the previous year. This can be seen as a signal that CSTL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 28 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Five small-cap stocks with strong growth potential for 2025 are TALK, RYAM, CSTL, PBAM, and RSSS.
Why It Matters - The mention of five small-cap stocks with strong growth potential signals opportunities for high returns, attracting investor interest in a competitive market.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Castle Biosciences ($CSTL) has been recognized as a Houston Top Workplace for the fourth consecutive year and received three national Culture Excellence awards.
Why It Matters - Castle Biosciences' recognition as a top workplace signals strong employee satisfaction and culture, potentially leading to improved productivity and retention, positively impacting financial performance.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Castle Biosciences ($CSTL) will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:50 am ET.
Why It Matters - Castle Biosciences' presentation at a key healthcare conference may influence investor sentiment and stock performance through insights on growth strategies and market positioning.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
Why It Matters - Castle Biosciences' upgrade to a Zacks Rank #1 suggests strong earnings potential, likely attracting more investment and driving the stock price higher.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Castle Biosciences (CSTL) has shown strong recent price performance and is considered well-positioned to continue its uptrend, according to a recent stock screening.
Why It Matters - Castle Biosciences (CSTL) shows strong recent performance, indicating potential for continued growth, which could attract investor interest and lead to increased stock demand.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Castle Biosciences' TissueCypher Barrett's Esophagus test has delivered over 25,000 reports since its acquisition in late 2021, indicating strong market adoption.
Why It Matters - Castle Biosciences' TissueCypher test showing strong adoption with over 25,000 reports suggests growing demand and potential revenue growth, positively impacting investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
